New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory disorders/autoimmune disorders

Current Signal Transduction Therapy

Volumn 6, Issue 2, 2011, Pages 279-291

  Wisler, Bradley A ^a   Dennis, James E ^a   Malemud, Charles J ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Autoimmunity; Inflammatory bowel diseases; JAK STAT; Organ specific drug delivery; P13K PTEN Akt mTOR; Rheumatoid arthritis; SAPK MAPK; Sj grens syndrome

Indexed keywords

ADALIMUMAB; ADENYLATE KINASE; ADIPONECTIN; ANTIGEN; ANTISENSE OLIGONUCLEOTIDE; APTAMER; B CELL ACTIVATING FACTOR; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; HERMES ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 14; JANUS KINASE; LIPOSOME; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NATALIZUMAB; NONIONIC SURFACTANT; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN CS1; PROTEIN KINASE B; RITUXIMAB; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ARTICLE; AUTOIMMUNE DISEASE; CELL MATURATION; CELL SURVIVAL; CROHN DISEASE; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; ENZYME ACTIVATION; EPITHELIUM CELL; EXOCRINE GLAND; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; TH1 CELL; ULCERATIVE COLITIS;

EID: 79957965350     PISSN: 15743624     EISSN: 15743624     Source Type: Journal    
DOI: 10.2174/157436211795659883     Document Type: Article

References (168)

1. Firestein G. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2005; 11: S39-S44. (Pubitemid 40863818)
2. Toh ML, Miossec P. The role of T cells in rheumatoid arthritis; new subsets and new targets. Curr Opin Rheumatol 2007; 19: 284-8. (Pubitemid 46597468)
3. + regulatory T cells in inflamed synovia. J Exp Med 2005; 201: 1793-803. (Pubitemid 41002898)
4. Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases; the effects of inflammation on bone. Immunol Rev 2005; 208: 228-51. (Pubitemid 41746396)
5. Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 2007; 5 : S4-S11. (Pubitemid 350176262)
6. Bugatti S, Codullo V, Caporali R, Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 2007; 6: 482-7. (Pubitemid 47069974)
7. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 289-95. (Pubitemid 46597469)
8. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmune Rev 2007; 6: 169-75. (Pubitemid 46187336)
9. Lotito AP, Silva CA, Mello SB. Interleukin-18 in chronic joint diseases. Autoimmun Rev 2007; 6: 253-6. (Pubitemid 46274551)
10. Malemud CJ, Miller AH. Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. Exp Opin Ther Targets 2008; 12: 171-83. (Pubitemid 351284960)
11. Malemud CJ, Reddy SK. Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis. Curr Rheumatol Rev 2008; 4: 219-34.
12. Malemud CJ. Recent advances in neutralizing the IL-6 pathway in arthritis. Open Access Rheumatology: Research and Reviews 2009; 1: 133-50.
13. Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 2005; 32: 1650-3. (Pubitemid 41324798)
14. Kaplan MH. STAT4. A critical regulator of inflammation in vivo. Immunol Res 2005; 31: 231-42.
15. Walker JG, Ahern MJ, Coleman M, et al. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 992-9. (Pubitemid 47122309)
16. Malemud CJ, Pearlman E. Targeting JAK/STAT signaling pathway in inflammatory diseases. Curr Signal Transduct Ther 2009; 4: 201-21.
17. Malemud CJ, Gillespie HJ. The role of apoptosis in arthritis. Curr Rheumatol Rev 2005; 1: 131-42.
18. Wu T, Mohan C. The AKT axis as a therapeutic target in autoimmune diseases. Endocr Metab Immune Disord Drug Targets 2009; 9: 145-50.
19. Malemud CJ. The discovery of novel experimental strategies for inflammatory arthritis. Mediators Inflamm 2009; 2009:698769.
20. Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 246-51. (Pubitemid 46597461)
21. Atreya R, Atreya I, Neurath MF. Novel signal transduction pathways. Analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann NY Acad Sci 2006; 1072: 98-113. (Pubitemid 44448446)
22. Inoue T, Boyle DL, Corr M, et al. Mitogen-activated protein kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc Natl Acad Sci USA 2006; 103: 5484-89.
23. Hashizume M, Hayakawa N, Mihara M. IL-6-trans-signalling directly influences RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology (Oxford) 2008; 47: 1635-40.
24. Abell K, Watson CJ. The Jak/Stat pathway: a novel way to regulate PI3K activity. Cell Cycle 2005; 4: 897-900. (Pubitemid 41359754)
25. Fujimoto M, Serada S, Mihara M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by inhibition of inflammatory Th17 responses. Arthritis Rheum 2008; 58: 3710-19.
26. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009; 7: CD007848.
27. Manoussakis MN, Kapsogeorgou EK. The role of epithelial cells in the pathogenesis of Sjögren's syndrome. Clin Rev Allergy Immunol 2007; 32: 225-30. (Pubitemid 350242568)
28. Manoussakis MN. Sjögren's syndrome or autoimmune epithelitis? Clin Rev Allergy Immunol 2007; 32: 199-200.
29. Garcia-Carrasco M, Fuentes-Alexandro S, Escárcega RO, Salgado G, Riebeling C, Cervera R. Pathophysiology of Sjögren's syndrome. Arch Med Res 2006; 37: 921-32.
30. Delaleu N, Immervoll H, Cornelius J, Jonsson R. Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther 2008; 10: R22.
31. Stea EA, Routsias JG, Samiotaki M, et al. Analysis of parotid glands of primary Sjögren's syndrome patients using proteomic technology reveals altered autoantigen composition and novel antigenic targets. Clin Exp Immunol 2007; 147: 81-9. (Pubitemid 44915558)
32. Nikolov NP, Illei GG. Pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol 2009; 21: 465-70.
33. Kawakami A, Nakashima K, Tamai M, et al. Toll-like receptor in salivary glands from patients with Sjögren's syndrome: functional analysis by human salivary gland cell line. J Rheumatol 2007; 34: 1019-26. (Pubitemid 46774848)
34. Spachidou MP, Bourazopoulou E, Maratheftis CI, et al. Expression of functional Toll-like receptor by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome. Clin Exp Immunol 2007; 147: 497-503. (Pubitemid 46208051)
35. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2007; 9: 491-502.
36. Mackay F, Groom JR, Tangye SG. An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol 2007; 19: 406-13. (Pubitemid 47344230)
37. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. Scand J Immunol 2005; 62:421-8. (Pubitemid 41719317)
38. Banica L, Besliu A, Pistol G, et al. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009; 42:41-9.
39. Shen L, Suresh L, Li H, et al. IL-14α, the nexus for primary Sjögren's disease in mice and humans. Clin Immunol 2009; 130: 304-12.
40. Shen L, Zhang C, Wang T, et al. Development of autoimmunity in IL-14α transgenic mice. J Immunol 2006; 177: 5676-86. (Pubitemid 44527644)
41. Zhong MC, Veillette A. Control of T lymphocyte signaling by Ly108, a signaling lymphocytic activation molecule family receptor implicated in autoimmunity. J Biol Chem 2008; 283: 19255-64.
42. Cruz-Munoz ME, Dong Z, Shi X, Zhang S, Veillette A. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2 on natural killer cell function. Nat Immunol 2009; 10: 297-305.
43. Lee JK, Mathew SO, Vaidya SV, Kumaresan PR, Mathew PA. CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes. J Immunol 2007; 179: 4672-8.
44. Nguyen CQ, Gao JH, Kim H, Saban DR, Cornelius JG, Peck AB. IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjögren's syndrome-like disease of the nonobsese diabetic mouse. J Immunol 2007; 179: 382-90. (Pubitemid 46986555)
45. Fletcher CA, Sutherland AP, Groom JR, et al. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur J Immunol 2006; 36: 2504-14. (Pubitemid 44420606)
46. Otipoby KL, Sasaki Y, Schmidt-Supprian M, et al. BAFF activates Akt and ERK through BAFF-R in an IKK-1-dependent manner in primary mouse B cells. Proc Natl Acad Sci USA 2008; 105: 12435-8.
47. Borchers AT, Naguwa SM, Keen CL, Gershwin ME. Immunopathogenesis of Sjögren's syndrome. Clin Rev Allergy Immunol 2003; 25: 89-104.
48. Shibata Y, Hishikawa Y, Izumi S, Fujita S, Yamaguchi A, Koji T. Involvement of Fas/Fas ligand in the induction of apoptosis in chronic sialadenitis of minor salivary glands including Sjögren's syndrome. Hum Cell 2002; 15: 52-60.
49. Abu-Helu RF, Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. Induction of salivary gland epithelial injury in Sjögren's syndrome: In vitro assessment of T-cell derived cytokines and Fas protein expression. J Autoimmun 2001; 17: 141-53. (Pubitemid 32928210)
50. Manganelli P, Fietta P. Apoptosis and Sjögren syndrome. Semin Arthritis Rheum 2003; 33: 49-65.
51. Nakamura H, Kawakami I, Ida H, Koji T, Eguchi K. Epidermal growth factor inhibits Fas-mediated apoptosis in salivary gland epithelial cells of patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2007; 25: 831-7. (Pubitemid 351166433)
52. Sisto M, Lisi S, Castellana D, et al. Autoantibodies from Sjögren's syndrome induce activation of both the intrinsic and extrinsic apoptotic pathways in human salivary gland cell line A-253. J Autoimmun 2006; 27: 38-49. (Pubitemid 44294853)
53. Sisto M, Lisi S, Lofrumento D, D'Amore M, Scagliusi P, Mitolo V. Autoantibodies from Sjögren's syndrome trigger apoptosis in salivary gland cell line. Ann NY Acad Sci 2007; 1108: 418-25. (Pubitemid 47528755)
54. Bulosan M, Pauley KM, Yo K, et al. Inflammatory caspases are critical for enhanced cell death in target tissue of Sjögrens syndrome before disease onset. Immunol Cell Biol 2009; 87: 81-90.
55. Katsiougiannis S, Tenta R, Skopouli FN. Activation of AMPactivated protein kinase by adiponectin rescues salivary gland epithelial cells from spontaneous and interferon-γ-induced apoptosis. Arthritis Rheum 2010; 62: 414-9.
56. Calafat M, Larocca L, Roca V, et al. Vasoactive intestinal peptide inhibits TNF-α -induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands. Arthritis Res Ther 2009; 11: R53.
57. Sisto M, D'Amore M, Caprio S, Mitolo V, Scagliusi P, Lisi S. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary gland. Ann NY Acad Sci 2009; 1171: 407-14.
58. Wang Y, Shnyra A, Africa C, Warholic C, McArthur C. Activation of the extrinsic apoptotic pathway by TNF-α in human salivary gland (HSG) cells in vitro, suggests a role for the TNF receptor (TNF-R) and intercellular adhesion molecule-1 (ICAM-1) in Sjögren's syndrome-associated autoimmune sialadenitis. Arch Oral Biol 2009; 54: 986-96.
59. Thum E, Shao Z, Schwarz H. CD137, implications in immunity and potential for therapy. Front Biosci 2009; 14: 4173-88.
60. Wilcox RA, Chapoval AI, Gorski KS, et al. Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol 2002; 168: 4262-7. (Pubitemid 34441322)
61. Kim DK, Lee SC, Lee HW. CD137 ligand-mediated reverse signals increase cell viability and cytokine expression in murine myeloid cells: involvement of mTOR/p70S6 kinase and Akt. Eur J Immunol 2009; 39: 2617-28.
62. Jonassen AK, Mjøs, Sack MN. P70s6 kinase is a functional target of insulin activated Akt cell-survival signaling. Biochem Biophys Res Commun 2004; 315: 160-5. (Pubitemid 38175200)
63. Ewert P, Aguilera S, Alliende C, et al. Disruption of tight junction structure in salivary glands from Sjögren's syndrome patients is linked to proinflammatory cytokine exposure. Arthritis Rheum 2010; 62: 1280-9.
64. Mariette X. Therapeutic potential for B-cell modulation in Sjögren's syndrome. Rheum Dis Clin North Am 2008; 34: 1025-33.
65. Perl A. Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjögren's syndrome. Curr Opin Rheumatol 2009; 21: 443-7.
66. Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment of Sjögren's syndrome. Arthritis Rheum 2009; 60: 3251-6.
67. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 960-8.
68. Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol 2004; 31: 96-101. (Pubitemid 38067529)
69. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebocontrolled pilot clinical trial. Arthritis Rheum 2004; 50: 2240-5. (Pubitemid 38930815)
70. Ghosh A, Chaki R, Mandal V, Lin GD, Mandal SC. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases. Int Rev Immunol 2010; 29: 4-37.
71. Mudter J, Weigmann B, Bartsch B, et al. Activation patterns of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol 2005; 100: 64-72. (Pubitemid 41623270)
72. Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann NY Acad Sci 2009; 1173: 350-6.
73. Fiorino G, Rovida S, Correale C, Malesci A, Danese S. Emerging biologics in the treatment of inflammatory bowel disease: What is around the corner? Curr Drug Targets 2010; 11: 249-60.
74. Mitsuyama K, Matsumoto S, Rose-John S, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/ Yit mice. Gut 2006; 55: 1263-9. (Pubitemid 44277357)
75. Schreiber S, Rosenstiel P, Hampe J, et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002; 51: 379-85.
76. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NY Hosp Joint Dis 2007; 65: S4-S10.
77. Yun L. Hanauer S. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2009; 3: 235-48.
78. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25. (Pubitemid 41565956)
79. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-97.
80. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-80.
81. Maini RN, Taylor PC, Szechinski J, et al. CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin- 6 receptor antagonist, tocilizumab in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29. (Pubitemid 44497760)
82. Hering NA, Schulzke JD. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig Dis 2009; 27: 450-4.
83. Felaco P, Castellani ML, De Lutiis MA, et al. IL-32: a newly discovered proinflammatory cytokine. J Biol Regul Homeost Agents 2009; 23: 141-7.
84. Kang JW, Choi SC, Cho MC, et al. A proinflammatory cytokine interleukin-32β promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology 2009; 128: e532-40.
85. Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007; 19: 400-8.
86. Sakuraba A, Sato T, Kamada N, Kitazume M, Sugita A, Hibi T. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 2009; 137: 1736-45.
87. Ouyang W, Filvaroff E, Hu Y, Grogan J. Novel therapeutic targets along the Th17 pathway. Eur J Immunol 2009; 39: 670-5.
88. Steinman L. Mixed results with modulation of TH-17 cells in autoimmune diseases. Nat Immunol 2010; 11: 41-4.
89. Caruso R, Sarra M, Stolfi C, et al. Interleukin-25 inhibits interleukin- 12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 2009; 136: 2270-9.
90. Andoh A, Shioya M, Nishida A, et al. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol 2009; 183: 687-95.
91. Brun V, Bastian H, Neveu V, Foussat A. Clinical grade production of IL-10 producing regulatory Tr1 lymphocytes for cell therapy of chronic inflammatory diseases. Int Immunopharmacol 2009; 9: 609-13.
92. Elliott M, Benson J, Blank M, et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann NY Acad Sci 2009; 1182: 97-110.
93. Bertrand MJ, Doiron K, Labbé K, Korneluk RG, Barker PA, Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 2009; 30: 789-801.
94. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009; 30: 383-91.
95. Lal-Nag M, Morin PJ. The claudins. Genome Biol 2009; 10: 235.
96. Schulzke JD, Ploeger S, Amasheh M, et al. Epithelial tight junctions in intestinal inflammation. Ann NY Acad Sci 2009; 1165: 294-300.
97. Stadnicki A, Machnik G, Klimacka-Nawrot E, Wolanska-Karut A, Labuzek K. Transforming growth factor-β1 and its receptors in patients with ulcerative colitis. Int Immunopharmacol 2009; 9: 761-6.
98. Mokrowiecka A, Gasiorowska A, Malecka-Panas E. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Hepatogastroenterology 2007; 54: 1443-8. (Pubitemid 47203445)
99. Bahari A, Aarabi M, Aarabi M et al. Diagnostic value of antineutrophil cytoplasmic antibodies and anti-Saccharocymes cerevisiae antibody in Iranian patients with inflammatory bowel disease. Acta Gastroenterol Belg 2009; 72: 301-5.
100. Lamacchia C, Palmer G, Seemayer CA, Talabot-Ayer D, Gabay C. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum 2010; 62: 452-62.
101. Fujimoto M, Serada S, Mihara M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by inhibition of inflammatory Th17 responses. Arthritis Rheum 2008; 58: 3710-9.
102. Schett G. Review: Immune cells and mediators in inflammatory arthritis. Autoimmunity 2008; 41: 224-9. (Pubitemid 351454993)
103. Malemud CJ. Growth hormone, VEGF and FGF: Involvement in rheumatoid arthritis. Clin Chim Acta 2007; 375: 10-9. (Pubitemid 44584237)
104. Nanki T, Takada K, Komano Y, et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 2009; 11: R149.
105. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006; 11: 529-43. (Pubitemid 43258162)
106. Aliprantis AO, Glimcher LH. NFATc1 in inflammatory and musculoskeletal conditions. In: Osteoimmunology: Advances in Experimental Medicine and Biology. Vol 658; Choi, Y (Editor), Springer, New York, 2010: pp. 69-75.
107. Leibbrandt A, Penninger JM. RANKL/RANK as key factors for osteoclastic differentiation and bone loss in arthopathies. Adv Exp Med Biol 2009; 649: 100-13.
108. Takaki R, Watson SR, Lanier LL. DAP12: an adapter protein with dual functionality. Immunol Rev 2007; 214: 118-29.
109. Takayanagi H. The unexpected link between osteoclasts and the immune system. In: Osteoimmunology: Advances in Experimental Medicine and Biology. Vol 658; Choi, Y (Editor), Springer, New York 2010: pp. 61-68.
110. Malemud CJ. Role of nonreceptor tyrosine and threonine kinase inhibitors. In: Molecular Biology of Cancer: Toward New Therapies. García-Foncillas, J (Editor) Prous Science, Barcelona, 2009: pp. 537-55.
111. Shinohara M, Koga T, Okamoto K et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 2008; 132: 794-806. (Pubitemid 351312796)
112. Kim Y-G, Lee C-K, Oh JS, Kim S-H, Kim K-A, Yoo B. Effect of IL-32γ on differentiation of osteoclasts from CD14+ monocytes. Arthritis Rheum 2010; 62: 515-23.
113. Tunyogi-Csapo M, Kis-Toth K, Radacs M, et al. Cytokinecontrolled RANK and osteoprotegerin expression by human and mouse fibroblasts. Fibroblast-mediated pathologic bone destruction. Arthritis Rheum 2008; 58: 2397-408.
114. Anandarajah AP. Role of RANKL in bone diseases. Trends Endocrinol Metab 2009; 20: 88-94.
115. Reedquist KA, Ludikhuize J, Tak PP. Phosphoinositide-3-kinase signalling and FoxO transcription factors in rheumatoid arthritis. Biochem Soc Trans 2006; 34: 727-30 (Pubitemid 44796406)
116. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide- 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-85.
117. Harris SJ, Foster JG, Ward SG. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies. Curr Opin Invest Drugs 2009; 10: 1151-62.
118. Hutcheson J, Perlman H. Apoptotic regulators and RA. Curr Rheum Rev 2008; 4: 254-8.
119. Scatizzi JC, Hutcheson J, Pope RM, et al. Bim-Bcl2 homology 3 mimetic therapy is effective in suppressing inflammatory arthritis through the activation of myeloid cell apoptosis. Arthritis Rheum 2010; 62: 441-51.
120. Pickens SR, Volin MV, Mandelin AM 2nd, Kolls JK, Pope RM, Shahrara S. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010; 184: 3233-41.
121. Rommel C, Camps M, Ji H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007; 7: 191-201.
122. Ameriks MK, Venable JD. Small molecule inhibitors of phosphoinositide- 3-kinase (PI3K) δ and γ. Curr Top Med Chem 2009; 9: 738-53.
123. Camps M, Rückle T, Ji H, et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-43. (Pubitemid 41294438)
124. Ghigo A, Damilano F, Braccini L, Hirsch E. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Bioessays 2010; 32: 185-96.
125. Ferrandi C, Ardissone V, Ferro P, et al. Phosphoinositide 3-kinase γ inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment. J Pharmacol Exp Ther 2007; 322: 923-30. (Pubitemid 47295804)
126. Wenink MH, Santegoets KC, Roelofs MF, et al. The inhibitory FcγIIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease. J Immunol 2009; 183: 4509-20.
127. Chiu Y-C, Lin C-Y, Chen C-P, et al. Peptidoglycan enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, focal adhesion kinase, Akt, and AP-1- dependent pathway. J Immunol 2009; 183: 2785-92.
128. Tan SY, Xiao L, Pi X, Holoshitz J. Aberrant Gi protein coupled receptor-mediated cell survival signaling in rheumatoid arthritis B cell lines. Front Biosci 2007; 12: 1651-60. (Pubitemid 46846797)
129. Ochaion A, Bar-Yehuda S, Cohen S, et al. The anti-inflammatory target A (3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell Immunol 2009; 258:115-22.
130. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol-3-kinase/Akt. J Biol Chem 2005; 280: 15709-18. (Pubitemid 40616690)
131. Cho ML, Ju JH, Kim KW, et al. Cyclosporine A inhibits IL-15- induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-κB. Immunol Lett 2007; 108: 88-96. (Pubitemid 46001466)
132. Ochaion A, Bar-Yehuda S, Cohen S, et al. The A3 adenosine receptor agonist CF502 inhibits PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol 2008; 76: 482-94.
133. Birkenkamp KU, Coffer PJ. Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem Soc Trans 2003; 31: 292-7. (Pubitemid 36241447)
134. Ludikhuize J, de Launay D, Groot D, et al. Inhibition of forkhead box class O family member transcription factors in rheumatoid synovial tissue. Arthritis Rheum 2007; 56: 2180-91. (Pubitemid 47173565)
135. Srivastava RK, Unterman TG, Shankar S. FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem 2010; 337: 201-12.
136. Malemud CJ, Schulte ME. Is there a final common pathway for arthritis? Future Rheumatol 2008; 3: 253-68. (Pubitemid 351984104)
137. Benito MJ, Murphy E, Murphy EP, van den Berg WB, FitzGerald O, Bresnihan B. Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1781-7. (Pubitemid 38725090)
138. Okamoto H, Yoshio T, Kaneko H, Yamanaka H. Inhibition of NF-κB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis. Arthritis Rheum 2009; 62: 82-92.
139. Caggiano TJ, Brazzale A, Ho DM, et al. Estrogen receptor dependent inhibitors of NF-κB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-κB, a potential treatment for rheumatoid arthritis. J Med Chem 2007; 50: 5245-8. (Pubitemid 350057835)
140. Andreakos S, Sacre S, Foxwell BM, Feldmann M. The toll receptor- nuclear factor κB pathway in rheumatoid arthritis. Front Biosci 2005; 10: 2478-88. (Pubitemid 40905252)
141. + cells of the bone marrow in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R54.
142. Saklatvala J. Inflammatory signaling in cartilage: MAPK and NF- κB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr Drug Targets 2007; 8: 305-13.
143. Sidiropoulos PI, Goulielmos G, Voloudakis GK, Petraki E, Boumpas DT. Inflammasomes and rheumatic diseases: evolving concepts. Ann Rheum Dis 2008 67:1382-89.
144. Ehrlich, P. 1957. Immunology and Cancer Research. Pergamon, London.
145. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-7. (Pubitemid 18091075)
146. Everts M, Koning GA, Kok RJ, et al. In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm Res 2003; 20: 64-72. (Pubitemid 36152919)
147. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364-6. (Pubitemid 26097120)
148. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998; 102: 430-7. (Pubitemid 28335203)
149. Zuo L, Huang Z, Dong L, et al. Targeting delivery of anti-TNF-α oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut 2010; 59: 470-9.
150. Kessner S, Krause A, Rothe U, Bendas G. Investigation of the cellular uptake of E-selectin-targeted immunoliposomes by activated human endothelial cells. Biochim Biophys Acta. 2001; 1514: 177-90. (Pubitemid 32831007)
151. Tan PH, Manunta M, Ardjomand N, et al. Antibody targeted gene transfer to endothelium. J Gene Med 2003; 5: 311-23. (Pubitemid 40310383)
152. Minaguchi J, Oohashi T, Inagawa K, Ohtsuka A, Ninomiya Y. Transvascular accumulation of sialyl Lewis X conjugated liposome in inflamed joints of collagen antibody-induced arthritic (CAIA) mice. Arch Histol Cytol 2008; 71:195-203.
153. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-80. (Pubitemid 28063372)
154. Lee L, Garrood T, Pitzalis C. In vivo phage display selection in the human/SCID mouse chimera model for defining synovial specific determinants. Methods Mol Med 2007; 136: 369-94.
155. Simonson AB, Schnitzer JE. Vascular proteomic mapping in vivo. J Thromb Haemost 2007; 5 Suppl 1: 183-7. (Pubitemid 46958832)
156. Hughes C, Faurholm B, Dell'Accio F, et al. Human single-chain variable fragment that specifically targets arthritis tissue. Arthritis Rheum 2010; 62: 1007-16.
157. Conrad R, Keranen LM, Ellington AD, Newton AC. Isozymespecific inhibition of protein kinase C by RNA aptamers. J Biol Chem 1994; 269: 32051-54.
158. Schneider DJ, Feigon J, Hostomsky Z, Gold L. High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 1995; 34: 9599-610.
159. Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamerdoxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 2006; 45:8149-52. (Pubitemid 44974149)
160. Orava EW, Cicmil N, Gariépy J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta 2010; 1798: 2190-200.
161. Gerlag DM, Borges E, Tak PP et al. Suppression of murine collagen- induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res 2001; 3: 357-61. (Pubitemid 33077115)
162. Krettek A, Sukhova GK, Schönbeck U, Libby P. Enhanced expression of CD44 variants in human atheroma and abdominal aortic aneurysm: possible role for a feedback loop in endothelial cells. Am J Pathol 2004; 165: 1571-81. (Pubitemid 39435156)
163. Hood E, Gonzalez M, Plaas A, Strom J, VanAuker M. Immunotargeting of nonionic surfactant vesicles to inflammation. Int J Pharm 2007; 339: 222-30. (Pubitemid 46977592)
164. Mrowietz U, Boehncke WH. Leukocyte adhesion: a suitable target for anti-inflammatory drugs. Curr Pharm Des 2006; 12: 2825-31. (Pubitemid 44184638)
165. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262: 509-25. (Pubitemid 47620502)
166. Ko IK, Kean TJ, Dennis JE. Targeting mesenchymal stem cells to activated endothelial cells. Biomaterials 2009; 30:3702-10.
167. Ko IK, Kim B-G, Awadallah A, et al. Targeting improves MSC treatment of inflammatory bowel disease, Mol Ther 2010; 18: 1365-72.
168. Schwager K, Kaspar M, Bootz F, et al. Preclinical characterization of DEKAVIL (F8-IL-10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009; 11: R142.